Akoya Biosciences, Inc. (AKYA)
| Market Cap | 239.49M |
| Revenue (ttm) | 91.37M |
| Net Income (ttm) | -71.40M |
| Shares Out | 49.08M |
| EPS (ttm) | -1.76 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 150,112 |
| Open | 5.03 |
| Previous Close | 5.08 |
| Day's Range | 4.80 - 5.06 |
| 52-Week Range | 3.04 - 12.90 |
| Beta | 1.43 |
| Analysts | Buy |
| Price Target | 8.00 (+63.93%) |
| Earnings Date | Nov 8, 2023 |
About AKYA
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microar... [Read more]
Financial Performance
In 2022, AKYA's revenue was $74.86 million, an increase of 36.31% compared to the previous year's $54.92 million. Losses were -$70.64 million, 59.2% more than in 2021.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for AKYA stock is "Buy." The 12-month stock price forecast is $8.0, which is an increase of 63.93% from the latest price.
News
Akoya to Participate at 42nd Annual J.P. Morgan Healthcare Conference
MARLBOROUGH, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in the 42nd Annual J...
Akoya Reports Record Revenue in the Third Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance
Q3 2023 revenue $25.2 million, 34% y/y growth Reiterating FY 2023 revenue guidance range of $95-98 million
Akoya to Participate at Three Upcoming Investor Conferences
MARLBOROUGH, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that Company management will be participating in t...
Akoya Biosciences to Showcase New Spatial Biology 2.0 Solutions and Spatial Phenotyping Data at SITC 2023
Spatial Biology 2.0 solutions enable discovery and translational workflows at an unprecedented speed and scale Global network of CROs providing Akoya's spatial phenotyping solutions will also exhibit ...
Akoya Biosciences Announces Peer-Reviewed Publication Using Ultrahigh-Plex Spatial Phenotyping of Head and Neck Cancer to Identify Distinct Immune and Metabolic Signatures
MARLBOROUGH, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that researchers from Akoya Biosciences and The Un...
Akoya to Report Third Quarter 2023 Financial Results on November 8th, 2023
MARLBOROUGH, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the thi...
Akoya Biosciences Sets a New Standard for Scaling Spatial Biology with the Launch of 2.0 Platforms
MARLBOROUGH, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today highlighted the industry-leading scale and speed in whole-s...
Akoya Reports Record Revenue in the Second Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance
Q2 2023 revenue $23.5 million, 31% y/y growth Reiterating FY 2023 revenue guidance range of $95-98 million
Akoya Biosciences Announces Milestone of 1,000 Peer-Reviewed Publications Citing Use of its Spatial Biology Technologies
MARLBOROUGH, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences , Inc. (Nasqad: AKYA)(“Akoya), The Spatial Biology Company®, today announced a momentous achievement - publication of the 1,000t...
Akoya to Report Second Quarter 2023 Financial Results on August 7th, 2023
MARLBOROUGH, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the sec...
Akoya to Participate at Two Upcoming Investor Conferences
MARLBOROUGH, Mass., June 12, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that Company management will be participating in t...
Akoya Biosciences Announces Pricing of Public Offering of Common Stock
MARLBOROUGH, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the pricing of its public offering of 8,700,000 sh...
Akoya Biosciences shares fall 10% on executive exits, stock offering
Shares of Akoya Biosciences AKYA, -2.46% on Wednesday dropped 10% to $5.00 in after-hours trading after the company said it fired its chief medical officer and chief people officer as part of a cost-c...
Akoya Biosciences Announces Public Offering of Common Stock
MARLBOROUGH, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced it has launched an underwritten public offering of...
Akoya Reports Record Revenue in the First Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance
Q1 2023 revenue $21.4 million, 27% y/y growth Reiterating FY 2023 revenue guidance range of $95-98 million
Akoya Biosciences Marks Milestone Achievement with Shipment of 1,000th Spatial Biology Instrument
MARLBOROUGH, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced it has shipped it's 1,000th instrument, a signifi...
Akoya Biosciences Introduces PhenoCode Discovery Panels to Simplify PhenoCycler-Fusion Workflow
MARLBOROUGH, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the launch of PhenoCode™ Discovery Panels, which ...
Akoya Biosciences and Enable Medicine Introduce Cloud Platform to Power Faster Analysis of PhenoCycler-Fusion Data
MARLBOROUGH, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced they are partnering with Enable Medicine to intro...
Akoya to Report First Quarter 2023 Financial Results on May 8th, 2023
MARLBOROUGH, Mass., April 06, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the fi...
Investment in procedural medical devices is safer for valuation, says E Squared's Les Funtleyder
Les Funtleyder, portfolio manager for E Squared Capital Management, joins 'The Exchange' to discuss big cap pharma's Q1 performance, the dollar weakness contributing to biotech gains, and investment o...
Akoya Biosciences Announces Leadership Transition
Joe Driscoll to Retire After More than Four Successful Years as Chief Financial Officer
Akoya Reports Record Revenue in the Fourth Quarter of 2022 and Provides Full Year 2023 Revenue Guidance
Q4 2022 revenue $21.2 million and FY 2022 revenue $74.9 million FY 2023 revenue guidance range $95-98 million
Akoya Biosciences Announces Appointment of Jennifer Kamocsay as General Counsel
MARLBOROUGH, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the appointment of Jennifer Kamocsay as General Co...
Akoya to Report Fourth Quarter and Full Year 2022 Financial Results on March 6th, 2023 and Participate at Two Upcoming Investor Conferences
MARLBOROUGH, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the fou...
Akoya Biosciences to Present First-of-its-Kind Spatial Multiomics Dataset at 2023 AGBT General Meeting
Simultaneous detection of proteins and RNA markers across 23 different tissue samples demonstrate robust and scalable capabilities of company's multiomics solution Simultaneous detection of proteins a...